Specific therapeutic targeting of epigenetic modifiers has emerged for chromatin reader protein BRD4 for MYC-dependent DLBCL (BET-domain inhibitors) [154], and EZH2 for mainly GCB-type DLBCL [190]. This evidence concerns the gene EZH2 and diffuse large B-cell lymphoma.